Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)

A Double-Blind, Multicenter, Placebo Controlled, Acute and Extension Study of 2 Doses of MK0869 in the Treatment of Patients With Major Depressive Disorder

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00034944

Enrollment

495

Registered

2002-05-03

Start date

2002-01-24

Completion date

2003-12-17

Last updated

2017-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder

Brief summary

A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression.

Detailed description

The duration of treatment is 8 weeks.

Interventions

DRUGMK0869, aprepitant

DRUGComparator: placebo

Study design

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Major depressive disorder

Design outcomes

Primary

Measure	Time frame
HAMD-17 total score at week 8. Tolerability.	—

Secondary

Measure	Time frame
CGI-I Scale score at week 8 and at least a 50% reduction in the HAMD-17 total score.	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026